耐药肺结核患者抗结核药物不良反应发生情况分析  

Incidence of Adverse Reactions Caused by Antituberculosis Drugs in Patients with Drug- resistant Pulmonary Tuberculosis

作　　者：曹兆兰[1] 李铁成[1] 赵丽[1] 

机构地区：[1]江苏省连云港市第四人民医院,222000

出　　处：《实用心脑肺血管病杂志》2016年第10期104-106,共3页Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease

摘　　要：目的分析耐药肺结核患者抗结核药物不良反应发生情况。方法选取2011年参与连云港市第四人民医院中国卫生部-盖茨基金会结核病防治项目的耐药肺结核患者51例,均采用标准化治疗方案6ZAm(Cm)LFx(Mfx)PAS(EMB)Pto/18ZLFx(Mfx)PAS(EMB)Pto进行治疗。查阅患者病历资料并记录耐药肺结核患者不良反应发生情况。结果不同性别、年龄段和耐药类型患者不良反应发生率比较,差异无统计学意义(P>0.05)。51例患者发生不良反应69次,其中胃肠道反应占37.7%(26/69)、肝脏毒性占24.6%(17/69)、关节痛或肌肉痛占13.0%(9/69)。患者出现不良反应后维持原治疗方案者46例,更换或调用药物者16例,调整用药剂量者4例,中断治疗者3例。结论耐药肺结核患者抗结核药物不良反应发生率较高,临床应重视对其不良反应的监测和处理,以保证治疗效果。Objective To analyze the incidence of adverse reactions caused by antituberculosis drugs in patients with drug- resistant pulmonary tuberculosis. Methods A total of 51 Patients with drug- resistant pulmonary tuberculosis registed in China Ministry of Health and the Gates Foundation for Tuberculosis Control Project were selected in the Fourth People＇s Hospital of Lianyungang in 2011, all of them received standardized treatment plan 〔6ZAm（ Cm） LFx（ Mfx） PAS（ EMB） Pto /18ZLFx（ Mfx） PAS（ EMB） Pto〕. The medical records were look up to analyze the incidence of adverse reactions caused by antituberculosis drugs. Results No statistically significant differences of incidence of adverse reactions caused by antituberculosis drugs was found in patients with different gender,age or drug resistance status（ P〉0. 05）. Of the 51 patients,69 times of adverse reactions were found,mainly including 26 times of gastrointestinal reactions（ accounting for 37. 7%）,17 times of hepatotoxicity（ accounting for 24. 6%）, 9 times of joint pain or muscle pain（ accounting for 13. 0%）. After occurrence of adverse reactions caused by antituberculosis drugs,46 cases maintained the original treatment plan,16 cases change the treatment drugs,4 cases adjust the dosage of medication,3 cases interrupted the treatment. Conclusion The incidence of adverse reactions caused by antituberculosis drugs is relatively high in patients with drug- resistant pulmonary tuberculosis,clinicians should pay attention to the monitoring and treatment for adverse reactions to guarantee the clinical outcome.

关 键 词：结核 肺 药物毒性 抗结核药 

分 类 号：R521[医药卫生—内科学]